Pre-market stock movers are a hot topic this morning and we’re checking out the biggest ones worth watching on Tuesday!
Moving stocks this morning are earnings reports, clinical trial results, and companies exploring strategic alternatives.
Let’s get into that news below!
Pre-Market Stock Movers: 10 Top Gainers
- Delcath Systems (NASDAQ:DCTH) stock is rocketing more than 65% following approval for its .
- G Medical Innovations (NASDAQ:GMVD) shares are soaring close to 22% alongside heavy pre-market trading.
- Sonim Technologies (NASDAQ:SONM) stock is surging nearly 21% with .
- T2 Biosystems (NASDAQ:TTOO) shares are gaining over 17% as it .
- Electriq Power (NYSE:ELIQ) stock is climbing more than 16% on Tuesday morning.
- FlexShopper (NASDAQ:FPAY) shares are increasing over 15% .
- LL Flooring (NYSE:LL) stock is rising more than 14% .
- Taysha Gene Therapies (NASDAQ:TSHA) shares are getting an over 13% boost with the release of its .
- Arena Group (NYSEMKT:AREN) stock is jumping more than 12% as a new investor .
- Grove Collaborative (NYSE:GROV) shares are up over 12% after releasing its .
10 Top Losers
- F45 Training (NYSE:FXLV) stock is crashing more than 62% after announcing the company will .
- Altisource Asset Management (NYSEMKT:AAMC) shares are plummeting over 62% with the release of its .
- Alaunos Therapeutics (NASDAQ:TCRT) stock is diving more than 49% after , announcing interim study data, and announcing it’s exploring strategic alternatives.
- Design Therapeutics (NASDAQ:DSGN) shares are tumbling over 41% with poor test results for its .
- TFF Pharmaceuticals (NASDAQ:TFFP) stock is taking a more than 33% beating after .
- MGO Global (NASDAQ:MGOL) shares are falling almost 32% alongside its .
- OptimizeRx (NASDAQ:OPRX) stock is dropping over 21% after releasing .
- Aptevo Therapeutics (NASDAQ:APVO) shares are sliding more than 21% this morning.
- Jet AI (NASDAQ:JTAI) stock is decreasing over 18% as it .
- Getty Images (NYSE:GETY) shares close out our pre-market stock movers down more than 18% on .
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
